| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/18/2001 | CA2378179A1 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 01/18/2001 | CA2377999A1 Compositions and methods for raising hdl cholesterol levels |
| 01/18/2001 | CA2377502A1 Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
| 01/17/2001 | EP1069132A1 Bicyclic derivatives of amino-pyrazinones, process of preparation and pharmaceutical compositions comprising them |
| 01/17/2001 | EP1069124A1 2-Benzimidazolylamine compounds as ORL1-receptor agonists |
| 01/17/2001 | EP1069114A2 Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| 01/17/2001 | EP1068869A2 Method and composition for ameliorating tissue damage due to ischemia and reperfusion |
| 01/17/2001 | EP1068868A2 Synergistic compositions comprising ascorbate and lysine for states related to extracellular matrix degeneration |
| 01/17/2001 | EP1068338A2 Enhanced prodrug activation |
| 01/17/2001 | EP1068240A1 Method for sterilising native collagen in liquid medium, resulting native collagen, compositions containing same and uses |
| 01/17/2001 | EP1068238A1 An integrin heterodimer and a subunit thereof |
| 01/17/2001 | EP1068236A1 Human oxidized ldl receptor |
| 01/17/2001 | EP1068221A2 Template associated npy y2-receptor agonists |
| 01/17/2001 | EP1068212A1 THIAZOLO 4,5-d]PYRIMIDINES AND PYRIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS |
| 01/17/2001 | EP1068207A1 AMINOALKYL SUBSTITUTED 9H-PYRIDINO 2,3-b]INDOLE AND 9H-PYRIMIDINO 4,5-b]INDOLE DERIVATIVES |
| 01/17/2001 | EP1068206A1 Aminoalkyl substituted pyrrolo 2,3-b]pyridine and pyrrolo 2,3-d]pyrimidine derivatives: modulators of crf1 receptors |
| 01/17/2001 | EP1068205A1 Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino 2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino 4,5-b]indole derivatives: crf1 specific ligands |
| 01/17/2001 | EP1068202A1 1-(3-heteroarylpropyl- or -prop-2-enyl)-4-benzylpiperidines used as nmda receptor antagonists |
| 01/17/2001 | EP1068191A1 Benzoxazinones/benzothiazinones as serine protease inhibitors |
| 01/17/2001 | EP1068180A1 Process for alkylating hindered sulfonamides useful in the production of matrix metalloprotenase inhibitors |
| 01/17/2001 | EP1068172A1 PLATELET AGGREGATION INHIBITION USING LOW MOLECULAR WEIGHT HEPARIN IN COMBINATION WITH A GP IIb/IIIa ANTAGONIST |
| 01/17/2001 | EP1067965A1 Pharmaceutical composition for treating cerebral apoplexy and craniocerebral trauma |
| 01/17/2001 | EP1067958A2 Treatment of cardiac hypertrophy |
| 01/17/2001 | EP1067953A1 Methods for treating an ischemic disorder and improving stroke outcome |
| 01/17/2001 | EP1067945A2 Methods for reducing cholesterol using bacillus coagulans spores, systems and compositions |
| 01/17/2001 | EP1067906A1 Maximizing effectiveness of substances used to improve health and well being |
| 01/17/2001 | EP1003501A4 Means of ascertaining an individual's risk profile for atherosclerotic disease |
| 01/17/2001 | EP0983258A4 N-hydroxy 4-sulfonyl butanamide compounds |
| 01/17/2001 | EP0786991B1 Polyamine compounds for treating vascular proliferative disorders |
| 01/17/2001 | EP0771216B1 Methods and compositions for the specific coagulation of tumoral vasculature |
| 01/17/2001 | EP0730590B1 isoxazoline and isoxazole fibrinogen receptor antagonists |
| 01/17/2001 | CN1280613A Isolated nucleic acid molecule encoding mammalian endoglucuronidase and uses therefor |
| 01/17/2001 | CN1280572A Inhibiting platelet derivative growth factor and/or quinoline and quinowoline compounds of P56lek tyrosinkinase |
| 01/17/2001 | CN1280570A Substituted fused heterocyclic compounds |
| 01/17/2001 | CN1280568A Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
| 01/17/2001 | CN1280501A Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 01/17/2001 | CN1280500A Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 01/17/2001 | CN1280498A Use of phospholipid complexes of extracts of i(vitis vinifera) as anti-atherosclerotic agent |
| 01/17/2001 | CN1280126A Substituted pyrazolyl benzene sulfone amides compounds for curing inflammation |
| 01/17/2001 | CN1280125A Substituted pyrazolyl benzene sulfone amides compounds for curing inflammation |
| 01/17/2001 | CN1280006A Medicine ointment prepared with kapur and other Chinese herbal medicine |
| 01/17/2001 | CN1279990A Medicine for curing hemiparalysis |
| 01/17/2001 | CN1279987A Medicine for curing piles |
| 01/17/2001 | CN1279981A Homorrholdal suppository of draconis sanguis and its producing method |
| 01/17/2001 | CN1279978A Ginkgo and gastrodia taber capsule |
| 01/17/2001 | CN1279970A Antilipemic blood circulation promoting xueluofu capsale |
| 01/17/2001 | CN1279951A Use of ecdysterone in preparing medicine for angiocardiopathy |
| 01/17/2001 | CN1060782C Preparation and application of sargassum polysaccharide complex |
| 01/17/2001 | CN1060767C Substituted benzene sulfonyl usea and benzene sulfonyl thiourea and mfg, method and use as raw material for medicine and medicine containing them |
| 01/17/2001 | CN1060764C Ortho-substituted benzoylguanidine, preparation method, use as medicine or diagnostic reagent and medicine containing them |
| 01/17/2001 | CN1060763C Urea-substituted benzoylguanidines, process for their preparation, and use and pharmaceutical containing them |
| 01/17/2001 | CN1060679C Use of combination of angiotensin-converting enzyme inhibitor and calcium antagonist for treatment of proteinuria |
| 01/17/2001 | CN1060665C Medicine for heart disease |
| 01/17/2001 | CN1060654C Oral liquid for treating cardiovascular diseases |
| 01/16/2001 | US6175021 Human non-pancreatic secretory phospholipase a2 (spla2); inhibits release of arachidonic acid to treat septic shock; ((3-(2-amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1h-indol-4 -yl)oxylacetic acid, for example |
| 01/16/2001 | US6175013 1-(2-methoxybenzyl)-2-((4-phenyl-1-piperazinyl)methyl)-4-(1h -indol-3-ylmethyl)-2-imidazoline, for example; adminstering to treat anxiety, depression, psychosis, and schizophrenia |
| 01/16/2001 | US6174994 7TM receptor (H2CAA71) |
| 01/16/2001 | US6174993 Short peptides which selectively modulate the activity of serine/threonine kinases |
| 01/16/2001 | US6174924 Treating nerve cell death comprising administering to a subject exhibiting symptoms of nerve cell death or susceptible to nerve cell death a substituted guanidine compound |
| 01/16/2001 | US6174923 Administering ethynyl alanine amino diol compound for treating hypertension |
| 01/16/2001 | US6174910 Treating pathological symptoms of vascular proliferation disorders which can be reduced or inhibited by apoptosis, by administering at.sub.1(angiotensin) receptor antagonist compound such as valsartan, irbesartan, losatran etc. |
| 01/16/2001 | US6174890 A synergistic biological, neurometabolic and celltrophic composition comprising antioxidative and -catabolic stress (methionine),-anabolic drugs, vasodilative and normo-lipidemic drugs (nicotinic acid), energoactive and antitoxic |
| 01/16/2001 | US6174887 Amide compounds and use of the same |
| 01/16/2001 | US6174884 1,5-dihydro-pyrazolo[34-D]-pyrimidinone derivatives |
| 01/16/2001 | US6174883 3-substituted-2-oxindoles derivatives |
| 01/16/2001 | US6174873 Oral administration of adenosine analogs |
| 01/16/2001 | US6174871 Gene therapies for enhancing cardiac function |
| 01/16/2001 | US6174676 Cytokine-stress- and oncoprotein-activated human protein kinase kinases |
| 01/16/2001 | CA2314008A1 2-benzimidazolylamine compounds as orl1-receptor agonists |
| 01/16/2001 | CA2200192C Amidino and guanidino substituted inhibitors of trypsin-like enzymes |
| 01/16/2001 | CA2021954C Substituted triazolinones, triazolinethiones and triazolinimines as angiotensin ii antagonists |
| 01/11/2001 | WO2001002866A1 Diagnostics and therapeutics for arterial wall disruptive disorders |
| 01/11/2001 | WO2001002604A1 Use of the krit1 gene in angiogenesis |
| 01/11/2001 | WO2001002569A2 Human immune response molecules |
| 01/11/2001 | WO2001002567A1 16405 receptor, a g-protein coupled receptor |
| 01/11/2001 | WO2001002565A2 Secreted protein zacrp4 |
| 01/11/2001 | WO2001002561A2 Mammalian calcium channels and related probes, cell lines and methods |
| 01/11/2001 | WO2001002550A2 Cell death related drug targets in yeast and fungi |
| 01/11/2001 | WO2001002443A1 Heparin compositions that inhibit clot associated coagulation factors |
| 01/11/2001 | WO2001002439A1 Neovascular-targeted immunoconjugates |
| 01/11/2001 | WO2001002406A1 Potassium channel blocking agents |
| 01/11/2001 | WO2001002398A1 Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them |
| 01/11/2001 | WO2001002397A1 Tricyclic compounds having spiro union |
| 01/11/2001 | WO2001002388A1 Indole derivatives and their use for the treatment of osteoporosis amongst other applications |
| 01/11/2001 | WO2001002387A1 N-imidazolylmethyl carboxamides as nitric oxide production inhibitors |
| 01/11/2001 | WO2001002381A1 Piperazine derivatives as modulators of chemokine receptor activity |
| 01/11/2001 | WO2001002379A1 Selective npy (y5) antagonists |
| 01/11/2001 | WO2001002376A1 Amino-alkyl derivatives |
| 01/11/2001 | WO2001002373A1 Dihydrobenzodiazepins and their use for treating dyslipidemia |
| 01/11/2001 | WO2001002369A2 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| 01/11/2001 | WO2001002363A2 N-substituted glycine derivatives |
| 01/11/2001 | WO2001002362A1 Azo amino acid derivatives for the treatment of neurological diseases |
| 01/11/2001 | WO2001002361A1 Beta-amino acid derivatives for the treatment of neurological diseases |
| 01/11/2001 | WO2001002360A1 Process for preparing amlodipine benzenesulphonate |
| 01/11/2001 | WO2001002356A1 Indoline or tetrahydroquinoline derivatives |
| 01/11/2001 | WO2001002029A1 Agent for occluding blood vessels |
| 01/11/2001 | WO2001001988A1 Compounds having cytokine inhibitory activity |
| 01/11/2001 | WO2001001987A1 Use of an angiotensin ii type 1 receptor antagonist in the manufacture of a medicament for the treatment of cardiovascular complications |
| 01/11/2001 | WO2001001986A1 Method of reducing neuronal injury or apoptosis |
| 01/11/2001 | WO2001001981A1 Vegf receptor antagonists |